An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) (AUD2OCU)

NCT00598611 Phase 3 COMPLETED

The purpose of this study is to compare urticaria lesions (size, kinetics) by thermography, volumetry and digital time lapse photography in CU patients treated with desloratadine 5 mg or desloratadine 20 mg. Hypothesis: Updosing of desloratadine (20mg) is more efficient in the treatment of urticarial lesions as compared to standard dosing (5 mg desloratadine).

Details

Lead sponsor	Charite University, Berlin, Germany
Phase	Phase 3
Status	COMPLETED
Enrolment	29
Start date	2007-09
Completion	2009-08

Conditions

• Chronic Urticaria

Interventions

• desloratadine
• desloratadine

Primary outcomes

• Reduction in size of existing spontaneous urticaria lesions (wheal and flare) as assessed by thermography. — 5 hours

Countries

Germany